



SHEET 1 OF 3

FORM PTO - 1449

ATTORNEY DOCKET NO.: LEX-004

## INFORMATION DISCLOSURE STATEMENT

APPLICANT(S): Gillies

SERIAL NO.: 09/292,217

FILING DATE: April 15, 1999 GROUP: 1646

## U.S. PATENT DOCUMENTS


EXAM. INIT.		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
FH	AA	4,196,265	4/1/80	Koprowski <i>et al.</i>	435	2	
	AB	4,816,567	3/28/89	Cabilly <i>et al.</i>	530	387	
	AC	5,225,539	7/6/93	Winter	530	387.3	
	AD	5,541,087	7/30/96	Lo <i>et al.</i>	435	697	
	AE	5,585,089	12/17/96	Queen <i>et al.</i>	424	133.1	
	AF	5,650,150	7/22/97	Gillies	424	134.1	
	AG	5,726,044	3/10/98	Lo <i>et al.</i>	435	69.7	
	AH	5,733,876	3/31/98	O'Reilly <i>et al.</i>	514	12	
	AI	5,837,682	11/17/98	Folkman <i>et al.</i>	514	12	
	AJ	5,854,205	12/29/98	O'Reilly <i>et al.</i>	514	2	
	AK	5,885,795	3/23/99	O'Reilly <i>et al.</i>	435	69.1	

## FOREIGN PATENT DOCUMENTS


EXAM. INIT.		DOCUMENT NUMBER	DATE	COUNTRY CODE	CLASS	SUB CLASS	FILING DATE	ABSTRACT ONLY	ENGLISH LANG Y/N

## OTHER ART, JOURNAL ARTICLES, ETC.

EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)								
FH	CA	Arenberg <i>et al.</i> (1996) "Interferon- $\gamma$ -inducible Protein 10 (IP-10) Is an Angiostatic Factor That Inhibits Human Non-small Cell Lung Cancer (NSCLC) Tumorigenesis and Spontaneous Metastases," J. EXP. MED. 184:981-992.							
FH	CB	Barnett <i>et al.</i> (1994) "Purification, characterization and selective inhibition of human prostaglandin G/H synthase 1 and 2 expressed in the baculovirus system," BIOCHIMICA ET BIOPHYSICA ACTA 1209:130-139.							
EXAMINER		Tom H. and			DATE CONSIDERED 6/12/00				



<b>FORM PTO - 1449</b>		<b>ATTORNEY DOCKET NO.: LEX-004</b>	
<b>INFORMATION DISCLOSURE STATEMENT</b>		<b>APPLICANT(S): Gillies</b>	
		<b>SERIAL NO.: 09/292,217</b>	
		<b>FILING DATE: April 15, 1999 GROUP: 1646</b>	
<b>OTHER ART, JOURNAL ARTICLES, ETC.</b>			
<b>EXAM. INIT.</b>	<b>OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)</b>		
FH	CC	Brooks <i>et al.</i> (1994) "Integrin $\alpha_v\beta_3$ Antagonists Promote Tumor Regression by Inducing Apoptosis of Angiogenic Blood Vessels," CELL 79:1157-1164.	
	CD	D'Amato <i>et al.</i> (1994) "Thalidomide is an inhibitor of angiogenesis," PROC. NATL. ACAD. SCI. USA 91:4082-4085.	
	CE	Gasson <i>et al.</i> (1984) "Purified Human Granulocyte-Macrophage Colony-Stimulating Factor: Direct Action on Neutrophils," SCIENCE 226:1339-1342.	
	CF	Gillies <i>et al.</i> (1989) "High-level expression of chimeric antibodies using adapted cDNA variable region cassettes," J. OF IMMUNOLOGICAL METHODS 125:191-202.	
	CG	Gillies <i>et al.</i> (1992) "Antibody-targeted interleukin 2 stimulates T-cell killing of autologous tumor cells," PROC. NATL. ACAD. SCI. USA 89:1428-1432.	
	CH	Gillies <i>et al.</i> (1998) "Antibody-IL-12 Fusion Proteins Are Effective in SCID Mouse Models of Prostate and Colon Carcinoma Metastases," J. OF IMMUNOL. 160:6195-6203.	
	CI	Gillis <i>et al.</i> (1978) "T Cell Growth Factor: Parameters of Production And A Quantitative Microassay for Activity," J. OF IMMUNOL. 6:2027-2032.	
	CJ	Huck <i>et al.</i> (1986) "Sequence of a human immunoglobulin gamma 3 heavy chain constant region gene: comparison with the other human Cy genes," NUCLEIC ACIDS RESEARCH 14:1779-1789.	
	CK	Huse <i>et al.</i> (1989) "Generation of a Large Combinatorial Library of the Immunoglobulin Repertoire in Phage Lambda," SCIENCE 246:1275-1281.	
	CL	Jones <i>et al.</i> (1986) "Replacing the complementarity-determining regions in a human antibody with those from a mouse," NATURE 321:522-525.	
	CM	Ingber <i>et al.</i> (1990) "Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth," NATURE 348:555-557.	
	CN	Kang <i>et al.</i> (1991) "Antibody redesign by chain shuffling from random combinatorial immunoglobulin libraries," PROC. NATL. ACAD. SCI. USA 88:11120-11123.	
	CO	LaVallie <i>et al.</i> (1993) "Cloning and Functional Expression of a cDNA Encoding the Catalytic Subunit of Bovine Enterokinase," J. OF BIOLOGICAL CHEMISTRY 268:23311-23317.	
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>	
[Signature]		6/12/00	



FORM PTO - 1449

## INFORMATION DISCLOSURE STATEMENT

ATTORNEY DOCKET NO.: LEX-004

APPLICANT(S): Gillies


SERIAL NO.: 09/292,217

FILING DATE: April 15, 1999 GROUP: 1646

## OTHER ART, JOURNAL ARTICLES, ETC.

EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)	
FH	CP	Lo <i>et al.</i> (1998) "High level expression and secretion of Fc-X fusion proteins in mammalian cells," PROTEIN ENGINEERING 11:495-500.
	CQ	Lode <i>et al.</i> (1998) "Natural Killer Cell-Mediated Eradication of Neuroblastoma Metastases to Bone Marrow by Targeted Interleukin-2 Therapy," BLOOD 91:1706-1715.
	CR	Maloney <i>et al.</i> (1994) "Phase I Clinical Trial Using Escalating Single-Dose Infusion of Chimeric Anti-CD20 Monoclonal Antibody (IDEC-C2B8) in Patients with Recurrent B-Cell Lymphoma," BLOOD 84:2457-2466.
	CS	Mestre <i>et al.</i> (1997) "Retinoids Suppress Epidermal Growth Factor-induced Transcription of cyclooxygenase-2 in Human Oral Squamous Carcinoma Cells," CANCER RESEARCH 57:2890-2895.
	CT	Nedwin <i>et al.</i> (1985) "Human lymphotoxin and tumor necrosis factor genes structure, homology and chromosomal localization," NUCLEIC ACIDS RESEARCH 13:6361-6373.
	CU	O'Reilly <i>et al.</i> (1994) "Angiostatin: A Novel Angiogenesis Inhibitor That Mediates the Suppression of Metastases by a Lewis Lung Carcinoma," CELL 79:315-328.
	CV	O'Reilly <i>et al.</i> (1997) "Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth," CELL 88:277-285.
	CW	Perez <i>et al.</i> (1989) "Isolation and Characterization of a cDNA Encoding the KS1/4 Epithelial Carcinoma Marker," J. OF IMMUNOLOGY 142:3662-3667.
	CX	Riethmuller <i>et al.</i> (1994) "Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma," THE LANCET 343:1177-1183.
	CY	Taniguchi <i>et al.</i> (1983) "Structure and expression of a cloned cDNA for human interleukin-2," NATURE 302:305-309.
	CZ	Varki <i>et al.</i> (1984) "Antigens Associated with a human lung adenocarcinoma defined by monoclonal antibodies," CANCER RESEARCH 44:681-687.
	CAA	Verhoeven <i>et al.</i> (1988) "Reshaping Human Antibodies: Grafting an Antilysozyme Activity," SCIENCE 239:1534-1536.
	CAB	Xiang <i>et al.</i> (1997) "Elimination of Established Murine Colon Carcinoma Metastases by Antibody-Interleukin 2 Fusion Protein Therapy," CANCER RESEARCH 57:4948-4955.
EXAMINER	DATE CONSIDERED 6/12/00	

FORM PTO - 1449 INFORMATION DISCLOSURE STATEMENT				ATTORNEY DOCKET NO.: LEX-004 APPLICANT(S): Gillies SERIAL NO.: 09/292,217 FILING DATE: April 15, 1999 GROUP: 1646					
U.S. PATENT DOCUMENTS									
EXAM. INIT.		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE		
Fit	AL	5,543,297	8/6/96	Cromlish <i>et al.</i>	435	25			
	AM	5,886,178	3/23/99	Allen <i>et al.</i>	544	238			
	AN	5,667,776	09/16/97	Zimmerman <i>et al.</i>	424	85.1			
FOREIGN PATENT DOCUMENTS									
EXAM. INIT.		DOCUMENT NUMBER	DATE	COUNTRY CODE	CLASS	SUB CLASS	FILING DATE	ABSTRACT ONLY	ENGLISH LANG Y/N
FW	BA	WO 92/08495	05/29/92	PCT					Y
	BB	WO 98/00127	01/08/98	PCT					Y
	BC	EP 706 799 A3	04/17/96	EP					Y
	BD	WO 89/09620	10/19/89	PCT					N
	BE	WO 92/02240	02/20/92	PCT					Y
	BF	WO 97/15666	05/01/97	PCT					Y
OTHER ART, JOURNAL ARTICLES, ETC.									
EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)								
Fit	CAC	Eisenthal, (1990) "Indomethacin up-regulates the generation of lymphokine-activated killer-cell activity and antibody-dependent cellular cytotoxicity mediated by interleukin-2," Cancer Immunol. Immunotherap. 31:342-348.							
	CAD	LeBerthon <i>et al.</i> (1991) "Enhanced Tumor Uptake of Macromolecules Induced by a Novel Vasoactive Interleukin 2 Immunoconjugate," Cancer Research 51:2694-2698.							
	CAE	Abstract XP-002116766, "Prostaglandins, their inhibitors and cancer" from Prostaglandins, Leukotrienes and Essential Fatty Acids (1996) 54(2): 83-94.							
EXAMINER				DATE CONSIDERED					

<b>FORM PTO - 1449</b>  <b>INFORMATION DISCLOSURE STATEMENT</b>				<b>ATTORNEY DOCKET NO.:</b> LEX-004  <b>APPLICANT(S):</b> Gillies  <b>SERIAL NO.:</b> 09/292,217  <b>FILING DATE:</b> April 15, 1999 <b>GROUP:</b> 1646					
 <b>U.S. PATENT DOCUMENTS</b>									
<b>EXAM. INIT.</b>		<b>DOCUMENT NUMBER</b>	<b>DATE</b>	<b>NAME</b>	<b>CLASS</b>	<b>SUB CLASS</b>	<b>FILING DATE IF APPROPRIATE</b>		
<b>FOREIGN PATENT DOCUMENTS</b>									
<b>EXAM. INIT.</b>		<b>DOCUMENT NUMBER</b>	<b>DATE</b>	<b>COUNTRY CODE</b>	<b>CLASS</b>	<b>SUB CLASS</b>	<b>FILING DATE</b>	<b>ABSTRACT ONLY</b>	<b>ENGLISH LANG Y/N</b>
<b>OTHER ART, JOURNAL ARTICLES, ETC.</b>									
<b>EXAM. INIT.</b>	<b>OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)</b>								
FH	CAF	Gillies <i>et al.</i> (1999) "Improving the Efficacy of Antibody-Interleukin 2 Fusion Proteins by Reducing Their Interaction with Fc Receptors," CANCER RESEARCH 59:2159-2166.							
<b>EXAMINER</b> <i>For H. Smith / JH</i>					<b>DATE CONSIDERED</b> <i>6/12/00</i>				